Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Operating Expenses (2022 - 2025)

Barinthus Biotherapeutics filings provide 3 years of Other Operating Expenses readings, the most recent being $4.7 million for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $4.7 million in Q3 2025 year-over-year; TTM through Mar 2026 was $4.7 million, a 61.77% decrease, with the full-year FY2025 number at $4.7 million, down 61.77% from a year prior.
  • Other Operating Expenses hit $4.7 million in Q3 2025 for Barinthus Biotherapeutics, down from $12.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $19.4 million in Q4 2022 to a low of -$10.8 million in Q3 2022.
  • Median Other Operating Expenses over the past 3 years was $4.7 million (2025), compared with a mean of $3.9 million.